Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.

Barbuch RJ, Campanale K, Hadden CE, Zmijewski M, Yi P, O'Bannon DD, Burkey JL, Kulanthaivel P.

Drug Metab Dispos. 2006 Feb;34(2):213-24. Epub 2005 Oct 28.

PMID:
16258078
2.

Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.

Perkins EJ, Cramer JW, Farid NA, Gadberry MG, Jackson DA, Mattiuz EL, O'Bannon DD, Weiss HJ, Wheeler WJ, Wood PG, Cassidy KC.

Drug Metab Dispos. 2003 Nov;31(11):1382-90.

PMID:
14570771
3.

Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog.

Burkey JL, Campanale KM, O'Bannon DD, Cramer JW, Farid NA.

Xenobiotica. 2002 Nov;32(11):1045-52.

PMID:
12487733
4.

Synthesis of [11C]dapoxetine.HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey.

Livni E, Satterlee W, Robey RL, Alt CA, Van Meter EE, Babich JW, Wheeler WJ, O'Bannon DD, Thrall JH, Fischman AJ.

Nucl Med Biol. 1994 May;21(4):669-75.

PMID:
9234326

Supplemental Content

Loading ...
Support Center